WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Good' (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...

Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release. The decision was supported by positive 1-year data from the phase 3 Pagoda study, in which Susvimo ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

Parapapillary outer temporal retina thickening can reveal diabetic retinopathy development in children with type 1 diabetes mellitus.

Protect your vision in 2025 with these 10 simple eye care habits, from screen breaks to a nutrient-rich diet, ensuring long-term eye health and clarity.

More than a million Brits could be living with undiagnosed diabetes, with early detection being key to managing the condition and maintaining a good quality of life ...